Biogen Idec competitive analysis

Explore Biogen Idec's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
Mar 26, 2025Methods Of Preventing And Removing Trisulfide Bonds5
Oct 2, 2024Methods And Products For Evaluating An Immune Response To A Therapeutic Agent1
Oct 18, 2023A Limiter For A Dispensing Device4
Feb 8, 2023Methods And Products For Evaluating An Immune Response To A Therapeutic Protein2
Aug 24, 2022Compositions And Uses For Treating Multiple Sclerosis16
Jun 29, 2022Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses Thereof2
Jun 22, 2022Immunoglobulin Chimeric Monomer-Dimer Hybrids2
Aug 14, 2019Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab1
Apr 24, 2019Method Of Assessing Risk Of Pml1
Feb 20, 2019A Method For The High Level Expression Of Active Lymphotoxin-Beta Receptor Immunoglobulin Chimeric Proteins And Their Purification1

Latest PTAB cases involving Biogen Idec

Discover the latest PTAB cases involving Biogen Idec, highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 29, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Biogen Idec

IPR2015-01993Sep 28, 2015COALITION FOR AFFORDABLE DRUGS VBIOGEN IDEC MAFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Biogen Idec with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIOGEN IDEC MA - 48 - 1
GENERICS UK TRADING MYLAN48 - - -
HEXAL976 - -
PHARMACEUTICAL WORKS POLPHARMA SA6 - - -